Current and emerging treatment options in triple-negative breast cancer

DİZDAR Ö., Altundag K.

ONCOLOGY REVIEWS, vol.4, no.1, pp.5-13, 2010 (ESCI) identifier identifier

  • Publication Type: Article / Review
  • Volume: 4 Issue: 1
  • Publication Date: 2010
  • Doi Number: 10.1007/s12156-009-0031-6
  • Journal Name: ONCOLOGY REVIEWS
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.5-13
  • Hacettepe University Affiliated: Yes

Abstract

Triple-negative breast cancer is defined by the lack of estrogen receptor, progesterone receptor and HER2 expression with immunohistochemical analysis. Triple-negative breast cancers are poorly differentiated, characterized by high histological grade and occur at a younger age. Treatment options are limited as these tumors are naturally resistant to existing targeted therapies, i.e., endocrine treatment and trastuzumab. An improved understanding of the biology of TNBC has led to evaluation of DNA-damaging chemotherapy drugs and targeted agents, including poly (ADP-ribose) polymerase inhibitors, epidermal growth factor receptor inhibitors, angiogenesis inhibitors, etc., in the treatment of TNBC. This review focuses on outlining the current and emerging treatment options in patients with triple-negative breast cancer.